Apricus Biosciences Incorporated (NASDAQ:APRI) Reports Decline in Sellers; Strong Momentum for Longs

October 13, 2017 - By Louis Casey

 Apricus Biosciences Incorporated (NASDAQ:APRI) Reports Decline in Sellers; Strong Momentum for Longs

The stock of Apricus Biosciences Incorporated (NASDAQ:APRI) registered a decrease of 6.64% in short interest. APRI’s total short interest was 1.54 million shares in October as published by FINRA. Its down 6.64% from 1.64 million shares, reported previously. With 493,500 shares average volume, it will take short sellers 3 days to cover their APRI’s short positions. The short interest to Apricus Biosciences Incorporated’s float is 27.01%.

The stock decreased 2.09% or $0.04 on October 13, reaching $1.87. About 155,664 shares traded. Apricus Biosciences Inc (NASDAQ:APRI) has declined 71.78% since October 13, 2016 and is downtrending. It has underperformed by 88.48% the S&P500.

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The company has market cap of $23.91 million. The Firm primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. It currently has negative earnings. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Apricus Biosciences Inc (NASDAQ:APRI) Ratings Coverage

Among 6 analysts covering Apricus Bioscience Inc (NASDAQ:APRI), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Apricus Bioscience Inc had 9 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, September 5 by H.C. Wainwright. H.C. Wainwright maintained the shares of APRI in report on Thursday, August 3 with “Buy” rating. The stock of Apricus Biosciences Inc (NASDAQ:APRI) has “Neutral” rating given on Wednesday, December 9 by Sterne Agee CRT. Roth Capital downgraded it to “Neutral” rating and $1.50 target in Friday, November 6 report. TH Capital downgraded Apricus Biosciences Inc (NASDAQ:APRI) on Friday, November 6 to “Neutral” rating. The company was initiated on Thursday, August 13 by Ascendiant Capital Markets. H.C. Wainwright maintained Apricus Biosciences Inc (NASDAQ:APRI) on Wednesday, August 30 with “Buy” rating. The stock of Apricus Biosciences Inc (NASDAQ:APRI) has “Outperform” rating given on Friday, November 6 by FBR Capital.

More notable recent Apricus Biosciences Inc (NASDAQ:APRI) news were published by: Globenewswire.com which released: “Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial …” on May 11, 2017, also Globenewswire.com with their article: “Apricus Biosciences to Present at the 2017 BIO Investor Forum” published on October 10, 2017, Seekingalpha.com published: “PDUFA Run-Up Idea: Apricus Biosciences” on September 04, 2017. More interesting news about Apricus Biosciences Inc (NASDAQ:APRI) were released by: Globenewswire.com and their article: “Apricus Biosciences Provides Corporate Update and Second Quarter 2017 …” published on August 02, 2017 as well as Seekingalpha.com‘s news article titled: “Apricus Biosciences’ (APRI) CEO Richard Pascoe on Q1 2017 Results – Earnings …” with publication date: May 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.